Open Access Open Access  Restricted Access Subscription or Fee Access

Exploration and Advancement of Drugs Within the Field of Bioinformatics: A Review

Pramod chikkodi, Rushikesh Balu Shendage

Abstract


After selection, research objectives fall under the supervision of either the pharmaceutical industry or pertinent academic institutions. The initial approach involves identifying drug molecules possessing the essential qualities necessary for the synthesis of targeted medications. Drug development constitutes the subsequent phase following the discovery of a drug and unfolds as a meticulous process aimed at introducing novel pharmaceuticals to the market. This intricate journey from discovery to market availability encompasses a substantial timeframe, often spanning two decades. Along this trajectory, the drug development process demands meticulous efforts, rigorous testing, and adherence to regulatory standards. The financial investment involved in this extensive undertaking can amount to a staggering $3 billion before the developed drug is deemed fit for clinical utilization. The pharmaceutical industry and academic institutions play a pivotal role in steering the course of research targets, overseeing the intricate process of drug development. The initial step involves discerning drug molecules endowed with the requisite properties, laying the foundation for subsequent phases. As drugs progress through the intricate stages of development, including pre-clinical and clinical trials, the cumulative investment of time and financial resources becomes evident. Ultimately, this exhaustive process aims to ensure that new drugs, backed by comprehensive research and testing, meet the stringent criteria for safety, efficacy, and regulatory approval before reaching the crucial stage of clinical utilization

Keywords


Drug discovery; drug development; methods; stages, regulatory

Full Text:

XML

References


Strovel J, Sittampalam S, Coussens NP, Hughes M, Inglese J, Kurtz A, et al. (July 1, 2016). "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies". Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences. PMID 22553881.

Jump up to:a b Taylor D (2015). "The Pharmaceutical Industry and the Future of Drug Development". Issues in Environmental Science and Technology. Royal Society of Chemistry: 1–33. doi:10.1039/9781782622345-00001. ISBN 978-1-78262-189-8.

Everts, Maaike; Cihlar, Tomas; Bostwick, J. Robert; Whitley, Richard J. (6 January 2017). "Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model". Annual Review of Pharmacology and Toxicology. 57 (1): 155–169. doi:10.1146/annurev-pharmtox-010716-104533. ISSN 0362-1642. PMID 27483339. Retrieved 2 November2021.

Jump up to:a b c d "The Drug Development Process". U.S. Food and Drug Administration (FDA). 4 January 2018. Retrieved 21 March 2020.

Kessler DA, Feiden KL (March 1995). "Faster evaluation of vital drugs". Scientific American. 272 (3): 48–54. Bibcode:1995SciAm.272c..48K. doi:10.1038/scientificamerican0395-48. PMID 7871409.

Madorran E, Stožer A, Bevc S, Maver U (2020). "In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research". Bosnian Journal of Basic Medical Sciences. 20 (2): 157–68. doi:10.17305/bjbms.2019.4378. PMC 7202182. PMID 31621554.

Ciociola AA, Cohen LB, Kulkarni P (May 2014). "How drugs are developed and approved by the FDA: current process and future directions". The American Journal of Gastroenterology. 109 (5): 620–3. doi:10.1038/ajg.2013.407. PMID 24796999. S2CID 205100166.

Jump up to:a b c d Strovel J, Sittampalam S, Coussens NP, Hughes M, Inglese J, Kurtz A, et al. (July 1, 2016). "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies". Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences. PMID 22553881.

"Vaccine Product Approval Process". U.S. Food and Drug Administration (FDA). 30 January 2018. Retrieved 21 March 2020.

Van Norman GA (June 2019). "Phase II Trials in Drug Development and Adaptive Trial Design". JACC. Basic to Translational Science. 4 (3): 428–437. doi:10.1016/j.jacbts.2019.02.005. PMC 6609997. PMID 31312766.

Fogel DB (September 2018). "Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review". Contemporary Clinical Trials Communications. 11: 156–164. doi:10.1016/j.conctc.2018.08.001. PMC 6092479. PMID 30112460.

"R&D costs are on the rise". Medical Marketing and Media. 38 (6): 14. June 1, 2003. Archived from the original on October 18, 2016.

Jump up to:a b "Clinical development success rates: 2006–2015" (PDF). BIO Industry Analysis. June 2016.

Wang Y (2012). "Extracting knowledge from failed development programmes". Pharmaceutical Medicine. 26 (2): 91–96. doi:10.1007/BF03256897. S2CID 17171991.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (March 2010). "How to improve R&D productivity: the pharmaceutical industry's grand challenge". Nature Reviews. Drug Discovery. 9 (3): 203–14. doi:10.1038/nrd3078. PMID 20168317. S2CID 1299234.

Prasad V, Mailankody S (November 2017). "Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval". JAMA Internal Medicine. 177 (11): 1569–1575. doi:10.1001/jamainternmed.2017.3601. PMC 5710275. PMID 28892524.

Jump up to:a b c d Moore TJ, Zhang H, Anderson G, Alexander GC (November 2018). "Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016". JAMA Internal Medicine. 178 (11): 1451–1457. doi:10.1001/jamainternmed.2018.3931. PMC 6248200. PMID 30264133.

Jump up to:a b DiMasi JA, Grabowski HG, Hansen RW (May 2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.

Taylor D (2015). "The Pharmaceutical Industry and the Future of Drug Development". Issues in Environmental Science and Technology. Royal Society of Chemistry: 1–33. doi:10.1039/9781782622345-00001. ISBN 978-1-78262-189-8.

Sertkaya A, Wong HH, Jessup A, Beleche T (April 2016). "Key cost drivers of pharmaceutical clinical trials in the United States". Clinical Trials. 13 (2): 117–26. doi:10.1177/1740774515625964. PMID 26908540. S2CID 24308679.

Herper M (11 August 2013). "The cost of creating a new drug now $5 billion, pushing Big Pharma to change". Forbes. Retrieved 17 July 2016.

Maxmen A (August 2016). "Busting the billion-dollar myth: how to slash the cost of drug development". Nature. 536 (7617): 388–90. Bibcode:2016Natur.536.388M. doi:10.1038/536388a. PMID 27558048.

Whipple, Tom (October 23, 2021). "Moonshot is the spanner in the Covid-19 works the country needs". The Times. Retrieved 5 November 2021.

Lee, Alpha; Chodera, John; von Delft, Frank (27 September 2021). "Why we are developing a patent-free Covid antiviral therapy". Knowable Magazine. doi:10.1146/knowable-092721-1. S2CID 244170138. Retrieved 1 November 2021.

Boris Bogdan and Ralph Villiger, "Valuation in Life Sciences. A Practical Guide", 2008, 2nd edition, Springer Verlag.

Nielsen, Nicolaj Hoejer "Financial valuation methods for biotechnology", 2010. "Archived copy" (PDF). Archived from the original(PDF) on 2012-03-05. Retrieved 2014-11-25.

Stratmann HG (September 2010). "Bad Medicine: When Medical Research Goes Wrong". Analog Science Fiction and Fact. CXXX (9): 20.

"R&D costs are on the rise". Medical Marketing and Media. 38 (6): 14. June 1, 2003. Archived from the original on October 18, 2016.

"Clinical Development Success Rates 2006-2015" (PDF). BIO Industry Analysis. June 2016.

Wang Y. (2012). "Extracting Knowledge from Failed Development Programmes". Pharm Med. 26 (2): 91–96. doi:10.1007/BF03256897. S2CID 17171991.

Herschel, M. (2012). "Portfolio Decisions in Early Development: Don't Throw Out the Baby with the Bathwater". Pharm Med. 26 (2): 77–84. doi:10.1007/BF03256895. S2CID 15782597. Archived from the original on 2012-06-16. Retrieved 2012-06-12.

"About the Innovative Medicines Initiative". European Innovative Medicines Initiative. 2020. Retrieved 24 January 2020.

"Critical Path Initiative". US Food and Drug Administration. 23 April 2018. Retrieved 24 January 2020.

"Breakthrough Therapy". US Food and Drug Administration. 4 January 2018. Retrieved 24 January 2020.

Jump up to:a b Shankland S (2020-03-23). "Sixteen supercomputers tackle coronavirus cures in the US". CNET. ViacomCBS. Retrieved 27 April 2020.

Jump up to:a b "The COVID-19 High Performance Computing Consortium". The COVID-19 High Performance Computing Consortium. 2020. Retrieved 2020-04-27.

Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, Visser SA (February 2019). "Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives". CPT. 8 (2): 87–96. doi:10.1002/psp4.12372. PMC 6389350. PMID 30411538.

"OpenPandemics – COVID-19". IBM. 2020. Retrieved 18 May 2020.




DOI: https://doi.org/10.37591/(rrjobi).v10i3.1515

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Research & Reviews: A Journal of Bioinformatics